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Prevalence of drug-drug interactions of antiretroviral agents 
in the private health care sector in South Africa
N L Katende-Kyenda, M S Lubbe, J H P Serfontein, I Truter
Human immunodeficiency virus (HIV) infection can now 
be effectively treated with the use of combination therapy, 
described as highly active antiretroviral therapy (HAART), 
requiring concomitant administration of three or four different 
agents, with a high potential for drug-drug interactions (DDIs)1 
and adverse drug reactions (ADRs).2 HAART consists of a 
backbone of two nucleoside reverse transcriptase inhibitors 
(NRTIs) and one non-nucleoside reverse transcriptase inhibitor 
(NNRTI) or one or two protease inhibitors (PIs), decreasing 
morbidity and mortality3 from opportunistic infections and 
making HIV infection a chronic disease.
HIV-infected individuals usually have an impaired immune 
response, and frequently develop opportunistic infections, 
malignancies, co-morbidity such as drug dependence, 
psychiatric disorders, and neurological manifestations of 
HIV or hepatic diseases, treatment of which requires a wide 
variety of drugs.4 Since both NNRTIs and PIs are extensively 
metabolised by the cytochrome P450 (CYP) system5 there 
is considerable potential for pharmacokinetic interactions 
when these drugs are administered concomitantly with drugs 
metabolised via the same pathway. 
The complexity of the drug regimen poses a significant 
challenge, in that there is a potential for a great number 
of DDIs. Antiretroviral (ARV) combinations can result in 
enhanced therapeutic efficacy, while others may augment the 
toxicity.6 To help the patient safely and effectively navigate the 
array of doses and drugs, the HIV/AIDS care provider should 
therefore have a comprehensive understanding of the key 
issues affecting the pharmacokinetic and pharmacodynamic 
effects of drug therapy, thus minimising DDIs and ADRs.
The prevalence of DDIs in ARVs has not yet been 
investigated in depth in private health care settings in South 
Africa. The aim of this study was therefore to determine the 
prevalence of possible DDIs between ARVs themselves and 
other drugs on prescriptions claimed for the year 2004. 
Methods
Study design
Permission to conduct the study was granted from Interpharm 
Datasystems and approved by the Research and Ethics 
Committees of North-West University, Potchefstroom campus, 
and Walter Sisulu University, Mthatha campus. This was a 
retrospective drug utilisation study done on ARVs claimed 
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Objectives. Human immunodeficiency virus (HIV) infection 
can be effectively treated with highly active antiretroviral 
therapy (HAART), requiring concomitant administration of 
three to four different agents, often with a high potential for 
drug-drug interactions (DDIs). This study aimed to determine 
the prevalence of possible DDIs between antiretrovirals 
(ARVs) themselves and other drugs.
Design. Retrospective drug utilisation study using data from a 
national medicine claims database for the period 1 January to 
31 December 2004. 
Setting. A section of the private health care sector in South 
Africa.
Subjects. All ARV prescriptions (N=43 482) claimed during 
2004. The possible DDIs found were classified according to 
a clinical significance rating described by Tatro (2005) in his 
book Drug Interaction Facts. 
Results. A total of 5 305 882 medicine items were prescribed; 
of these, 1.92%  (N=101 938) were ARVs. Of the total number 
of 2 595 254 prescriptions, 1.68% (N=43 482) contained ARVs. 
A total number of 18 035 DDIs (81 different types) were 
identified; of these, 83.89% (N=15 130) were DDIs between 
ARVs and other drugs, while 16.11% (N=2 905) were DDIs 
between ARVs themselves. Possible DDIs with a clinical 
significance level of 1 (major, N=17) and 2 (moderate,  
N=1 436) represented 8.06% (N=1 453) of the total number of 
identified interactions. 
Conclusions. Since concomitant use of ARVs and other drugs 
used to treat HIV complications is increasing, there is a need 
to understand and anticipate these DDIs and to overcome 
them by dose adjustments and patient education, so that they 
are not life threatening to HIV/AIDS patients.     
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through a national medicine claims database for the period 
1 January 2004 to 31 December 2004. During 2004, this medical 
scheme administrator administered data for 80 medical 
schemes. The focus of this study was on the prevalence of 
possible DDIs between ARVs themselves and other drugs 
on the same prescription. The possible DDIs found in this 
study were classified according to a clinical significance rating 
expressed as a number assigned to each DDI based on the 
severity and documentation of the interaction, as follows: 
1 (major), 2 (moderate), 3 (minor), 4 (major/moderate) and 5 
(minor/any), as described by Tatro.7
Three degrees of severity were identified, namely major, 
moderate and minor:7
•    Major effects are potentially life threatening, capable of 
causing permanent damage, and necessitating additional 
treatment, hospitalisalisation or extension of hospital stay. 
•    Moderate effects may cause deterioration of a 
patient’s clinical status, requiring additional treatment, 
hospitalisation or extension of hospital stay.
•    Minor effects are usually mild, having bothersome or 
unnoticeable consequences but not significantly affecting 
the therapeutic outcome. Additional treatment is usually 
not required.
The following documentation levels can be distinguished, 
namely established, probable, suspected, possible and unlikely. 
The scale represents an evaluation of the quality and clinical 
relevance of the primary literature supporting the occurrence 
of an interaction.7 Drug interactions assigned documentation 
levels of established, probable, or suspected are considered to 
be well substantiated and have significance ratings of 1, 2 or 3. 
These interactions are considered probable, while interactions 
of significance ratings 4 or 5 are not substantiated, having 
documentation levels of possible or unlikely.
Study population
The study population consisted of all ARV prescriptions 
(N=43 482) claimed during 2004. 
Study protocol
The data consisted of ARV drug names and others prescribed 
on the same prescription. The ARVs were classified according 
to pharmacological groups as described in the Monthly Index 
of Medical Specialties (MIMS).8 Drug interactions were detected 
using a previously developed computerised drug interaction 
database system. 
According to the Medicines Control Council of South Africa,9 
14 ARVs (NRTIs, NNRTIs and PIs) were registered during the 
period 1989 - 2004.
Statistical analysis
The data were obtained directly from the Interpharm 
Datasystems and analysed  using the Statistical Analysis 
System, SAS 9.1.10 There was no direct manipulation of the data 
by the researcher. Research was conducted on the assumption 
that all data obtained from the medicine claims database were 
correct and accurate. Data for the analysis were obtained from 
one medicine claims database, thus limiting external validity, 
and implying that results can only be generalised to the specific 
database used, as well as to the specific study population. No 
specific patient, medical practice, pharmacy or medical scheme 
could be identified; confidentiality of information was thus 
maintained throughout the study.
Results 
A total of 5 305 882 medicine items were prescribed; of 
these, 1.92% (N=1 01 938) were ARVs. Of the total number of 
2 595 254 prescriptions, 1.68% (N=43 482) contained ARVs. 
A total number of 18 035 DDIs (81 different types) were 
identified; of these, 83.89% (N=15 130) were DDIs between 
ARVs and other medications, while 16.11% (N=2 905) were 
DDIs between ARVs themselves. Possible DDIs with a clinical 
significance level of 1 (major, N=17) and 2 (moderate, N=1 436) 
represented 8.06% (N=1 453) of the total number of identified 
interactions. The frequencies of level 3 to 5 interactions were: 
3 – N=1 221; 6.77%, 4 – N=6 678; 37.03%, and 5 – N=8 683; 
48.14%. Level 1 interactions were between: (i) indinavir and 
lanzoprazole (N=3; 17.65%), omeprazole (N=2; 11.76%) and 
simvastatin (N=1; 5.88%); (ii) ritonavir and simvastatin (N=4; 
23.53%), digoxin (N=5; 29.41%) and fentanyl (N=1; 5.88%); and 
(iii) saquinavir and fentanyl (N=1; 5.88%). The most prevalent 
(more than 100) level 2 DDIs between ARVs themselves were: 
indinavir and ritonavir (N=490), efavirenz and ritonavir 
(N=274), efavirenz and indinavir (N=198), didanosine and 
indinavir (N=121) and efavirenz and lopinavir/ritonavir 
(N=118), as set out in Table I. Level 2 interactions between 
ARVs and other drugs are set out in Table II. 
Discussion
The aim of this study was to determine the prevalence of 
possible DDIs between ARVs themselves and other drugs 
on prescriptions claimed in a section of the private health 
care sector in South Africa. This study indicated that the 
prescriptions of ARVs accounted for 1.68% (N=43 482) of the 
total number of prescriptions (N=2 595 254) claimed from the 
database. Eighty-one different types of DDIs were identified; 
of these 83.89% (N=15 130) were DDIs between ARVs and 
other medications, and 16.11% (N=2 905) were between ARVs 
themselves. HIV-infected individuals usually receive a wide 
variety of drugs in addition to their ARV drug regimen. Since 
both NNRTIs and PIs are extensively metabolised by the 
cytochrome P450 system, there is a considerable potential for 
pharmacokinetic drug interactions when they are administered 
concomitantly with other drugs metabolised via the same 
pathway. In addition, PIs are substrates as well as inhibitors 
of the drug transporter plasma membrane glycoprotein (P-
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Table I. Frequency of level 2 interactions between ARVs themselves
ARVs interacting between themselves    N       %*
Indinavir (PI) and ritonavir (PI)    490    36.95
Efavirenz (NNRTI) and  ritonavir (PI)    274    20.66
Efavirenz (NNRTI) and indinavir (PI)    198    14.93
Didanosine (NRTI) and indinavir (PI)    121      9.13
Efavirenz (NNRTI) and lopinavir/ritonavir (PI)   118      8.90
Efavirenz (NNRTI) and  saquinavir (PI)       1      0.08
Efavirenz (NNRTI) and saquinavir (PI)       1      0.08
Nevirapine (NNRTI) and lopinavir/ritonavir PI)    49      3.70
Nelfinavir (PI) and  nevirapine (NNRTI)       2      0.15
Nevirapine (NNRTI) and saquinavir (PI)      5      0.38
Nevirapine (NNRTI)  and ritonavir (PI)                  3.39
Indinavir (PI) and lopinavir/ritonavir (PI)      9      0.68
Indinavir (PI) and nevirapine (NNRTI)     13      0.98
Total                   1 326   100.00
*Percentages were calculated according to the total number of interactions presented. 
NRTI = nucleoside reverse transcriptase inhibitor; NNRTI = non-nucleoside reverse transcriptase inhibitor; PI = protease inhibitor. 
Table II. Frequency of level 2 interactions between ARVs and the other drugs
Interacting ARVs and other drugs    N   %*
Didanosine + ketoconazole     1   0.91
Didanosine + ofloxacin     1   0.91
Didanosine + ciprofloxacin     2   1.82
Didanosine + iraconazole     3   2.73
Didanosine + ketoconazole     2   1.82
Efavirenz + alprazolam     6   5.45
Efavirenz + methadone     4   3.64
Efavirenz + triazolam     4   3.64
Indinavir + fluconazole     7   6.36
Indinavir + itraconazole     7   6.36
Indinavir + ketoconazole     4   3.64
Lopinavir + fluconazole     2   1.82
Lopinavir + itraconazole     2   1.82
Lopinavir/ritonavir + alprazolam    1   0.91
Lopinavir/ritonavir + chlordiazepoxide    3   2.73
Lopinavir/ritonavir + diazepam    1   0.91
Lopinavir/ritonavir + fluconazole                  15                 13.64
Lopinavir/ritonavir + itraconazole    2   1.82
Ritonavir + alprazolam     3   2.73
Ritonavir + chlordiazepoxide     3   2.73
Ritonavir + diazepam     1   0.91
Ritonavir + fluconazole                    16                 14.55
Ritonavir + itraconazole     2   1.82
Ritonavir + fluoxetine     2   1.82
Ritonavir + piroxicam     2   1.82
Ritonavir + pravastatin     2   1.82
Ritonavir + zolpidem hemitartate    3   2.73
Saquinavir + chlordiazepoxide    2   1.82
Saquinavir + diazepam     1   0.91
Saquinavir + fluconazole     2   1.82
Saquinavir mesylate + fluconazole    2   1.82
Saquinavir mesylate + alprazolam    2   1.82
Total                   110               100.00
*Percentages were calculated according to the total number of interactions presented. 
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gp) that can result in pharmacokinetic drug interactions. The 
NRTIs are predominantly excreted by the renal system and 
may give rise to interactions.4 
Possible DDIs with a clinical significance level of 1 (N=17) 
and 2 (N=1 436) represented 8.06% (N=1 453) of the total 
number of possible interactions identified in this study. Level 
1 interactions were between (i) indinavir and lanzoprazole, 
omeprazole and simvastatin; (ii) ritonavir and simvastatin, 
digoxin and fentanyl;  and (iii) saquinavir and fentanyl. 
Indinavir and ritonavir are PIs, inhibitors of the CYP 3A4 
enzyme that is important for the metabolism of several 
drugs, which increases the probability of pharmacokinetic 
interactions between PIs and drugs taken concomitantly. The 
interaction between ritonavir and simvastatin is supported by 
Clotet and Negredo,11 who report that PI administration may 
be associated with alterations in plasma lipids and insulin 
levels, placing some PI-treated patients at increased risk for 
coronary heart disease. Statins are an important component of 
pharmacotherapy for PI-associated dyslipidaemia, but, because 
all except pravastatin are metabolised by the CYP450 enzyme 
system, concomitant use of these agents produces a substantial 
risk of drug interactions and statin-induced hepatotoxicity 
and myopathy.1 Fortunately new PIs are available that do not 
adversely affect plasma lipid levels. 
Interactions between ritonavir and digoxin accounted for 
29.41% (N=5) of possible level 1 DDIs in this study. Ritonavir 
has been reported to decrease total digoxin clearance at renal 
and non-renal levels,12 and therapeutic doses of ritonavir 
also inhibits drug transport and metabolism in humans. 
Concomitant use of ritonavir with digoxin, a P-gp substrate, 
therefore requires major dose adjustments.
In this study interaction of ritonavir with fentanyl accounted 
for 5.88% (N=1) of possible level 1 reactions. Among HIV PIs, 
ritonavir is the most potent inhibitor of CYP3A4. Fentanyl, a 
synthetic opioid analgesic is metabolised mainly by CYP3A4. 
A study13 revealed that ritonavir profoundly affected the 
pharmacokinetics of fentanyl, reducing its clearance by 67% 
and increasing and prolonging fentanyl-induced respiratory 
depression. It is therefore advisable to maintain respiratory 
monitoring for longer than usual in patients on these two 
drugs.
Combinations of ARVs are being used to augment and 
prolong their virological and immunological benefits, and also 
to delay the emergence of resistance. ARVs, especially the PIs, 
have a strong potential to interact with each other. In particular, 
the NNRTIs metabolised by CYP3A4 have shown to interact 
with PIs, which are inhibitors of CYP3A4, especially ritonavir, 
a potent inhibitor. In our study interactions between indinavir 
and ritonavir accounted for 36.95% (N=490) of possible level 2 
DDIs between ARVs themselves. Administration of ritonavir 
improves the bioavailability and prolongs the elimination half-
life of indinavir, reducing the total dose necessary to achieve a 
potent ARV plasma concentration. It is therefore recommended 
that patients be closely monitored so that the dose can be 
adjusted when necessary.
This study revealed a possible DDI between ritonavir and 
efavirenz, with a prevalence of 20.66% (N=274) of possible level 
2 DDIs between ARVs themselves. An interaction between 
ritonavir and efavirenz has been reported13 in 20 healthy 
volunteers who received efavirenz 200 mg daily and ritonavir 
up to 600 mg twice daily. With this combination, the area under 
the curve (AUC) for efavirenz increased by 21% and that for 
ritonavir by 17%, leading to the conclusion that if patients 
experience intolerance to ritonavir while on efavirenz, the 
ritonavir dosage could be reduced to 500 mg twice daily. 
Interactions between efavirenz and indinavir accounted 
for 14.93% (N=198) of possible level 2 DDIs between ARVs 
themselves in our study. This finding is supported by a study14 
reporting that the addition of efavirenz to a combination of 
800 mg indinavir and 100 mg ritonavir twice daily resulted 
in significant decreases in AUC, Cmax, and especially Cmin of 
indinavir. Efavirenz is a potent inducer of CYP3A4, suggesting 
a potential interaction between this NNRTI and PIs that inhibit 
CYP3A4. It is recommended that the dose of indinavir or 
ritonavir be increased to maintain indinavir drug levels when 
efavirenz is added to the indinavir-ritonavir combination.
Interactions of didanosine with indinavir accounted 
for 9.13% (N=121) of possible level 2 DDIs between ARVs 
themselves in our study. Various combinations of NRTIs and 
PIs are acceptable as HAART: to overcome the induction of 
PI metabolism by the NRTIs, administration of indinavir 
and didanosine separately at least 1 hour apart on an empty 
stomach is therefore recommended.     
Drugs used to treat opportunistic infections could influence 
the occurrence of ADRs to ARVs. In this study the azoles 
(ketoconazole, fluconazole and itraconazole), used to treat 
fungal infections, interacted with PIs at level 2. A patient taking 
ritonavir 600 mg twice daily and saquinavir 400 mg twice 
daily is reported to have developed symptoms of PI toxicity 1 
week after itraconozole was increased from 100 mg to 200 mg 
twice daily,15 and 2 of 4 patients receiving indinavir developed 
hyperbilirubinaemia and slightly elevated transaminase levels 
while on itraconazole. Levels returned to pretreatment values 
after discontinuing itraconazole. Fluconazole is a less potent 
inhibitor of CYP3A4, so may be a better tolerated alternative. 
The PIs in this study interacted with benzodiazepines 
at level 2. Large increases in serum concentrations of 
benzodiazepines undergoing oxidative metabolism due to 
inhibition of hepatic metabolism (CYP3A4) may cause severe 
sedation and respiratory depression. Prolonged sedation 
was reported in a 32-year-old patient receiving intravenous 
midazolam for bronchoscopy after administration of saquinavir 
but not after midazolam alone.16 Co-administration of PIs with 
benzodiazepines is therefore contraindicated.
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Conclusion
In this study DDIs have been identified between ARVs 
themselves and between ARVs and other drugs. Managing 
these DDIs is one of the major challenges associated with 
the multidrug regimens used for HIV therapy. Some of these 
DDIs can be overcome by dose adjustments and by advising 
the patient to take some drugs separately. Other DDIs are not 
considered clinically life threatening.   
Limitations of the study
The followings should be taken into consideration when 
evaluating these results.
•    Only the prescription data were available to the researchers. 
It was not possible to gain any demographic or clinical 
information on the patients.
•    The clinical relevance of the identified DDIs was evaluated 
according to criteria stated in the literature. No clinical 
evaluation of the real effects of these interactions was 
possible. However, the results emphasised the possibility 
of DDIs that could have led to severe problems. Further 
research into the usage of ARVs in the private health care 
sector should therefore be conducted in South Africa. 
•    Various combinations of NNRTIs and PIs are acceptable as 
HAART, with dosage adjustments of PIs, but in this study 
dosage adjustments were not investigated; we therefore 
recommend that further studies be done. 
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